COCRYSTAL PHARMA, INC. Payments of Financing Costs
COCRYSTAL PHARMA, INC. (COCP) reported Payments of Financing Costs of $36.30 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2014-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2014-03-31
- COCRYSTAL PHARMA, INC. payments of financing costs for the quarter ending 2012-12-31 was $0.00.
- COCRYSTAL PHARMA, INC. payments of financing costs for the quarter ending 2012-09-30 was $11.30K.
- COCRYSTAL PHARMA, INC. payments of financing costs for the quarter ending 2011-12-31 was $0.00.
- COCRYSTAL PHARMA, INC. payments of financing costs for the quarter ending 2011-09-30 was $0.00.
- COCRYSTAL PHARMA, INC. payments of financing costs for fiscal 2012 was $36.30K, a 75.86% decline from fiscal 2011.
- COCRYSTAL PHARMA, INC. payments of financing costs for fiscal 2011 was $150.36K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $11.30K derived: sum of 2 quarters · filed 2014-03-31 | $36.30K 10-K · filed 2014-03-31 | |
| 2012-09-30 | $11.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-18 | $36.30K 10-Q · filed 2013-11-18 | ||
| 2012-06-30 | $25.00K 10-Q · filed 2013-08-15 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-01 | $0.00 derived: sum of 2 quarters · filed 2013-04-01 | $0.00 derived: sum of 3 quarters · filed 2013-04-01 | $150.36K 10-K · filed 2013-04-01 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | $0.00 derived: sum of 2 quarters · filed 2012-11-14 | $150.36K 10-Q · filed 2012-11-14 | |
| 2011-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2012-09-28 | $150.36K 10-Q/A · filed 2012-09-28 | ||
| 2011-03-31 | $150.36K 10-Q/A · filed 2012-10-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |